Norovirus

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

Retrieved on: 
Monday, February 5, 2024
Death, VLP, AGE, Norovirus, Vaccine

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines.

Key Points: 
  • HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines.
  • Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
  • The burden of norovirus falls disproportionately on young children and older adults.
  • For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Retrieved on: 
Monday, February 5, 2024
SARS-CoV-2, COVID-19, SAN, Norovirus, Volatile organic compound, Vaxart, Animal, Disease, Immunoglobulin G, Vaccination, Infection, Immunoglobulin A, VOC, Serum, Development, Immunization, Vaccine

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s. The data, which were previously presented at the International Congress of Mucosal Immunology 2022, are reported in the current issue of Vaccines.

Key Points: 
  • “The data published in Vaccines support the potential of our vaccine platform to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission.
  • All three vaccines induced neutralizing antibodies in both the peripheral and mucosal compartments, which was enhanced with a boost immunization.
  • Viral replication and infectious particle shedding were significantly reduced in immunized animals after challenge with beta variant SARS-CoV-2.
  • Vaxart believes these data support the potential for its vaccines to enhance mucosal responses and reduce community transmission, in addition to preventing severe disease.

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

Retrieved on: 
Thursday, January 18, 2024
Doctor of Philosophy, RSV, Vaccine, GSK, Norovirus, MD, Pharmaceutical industry

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer.

Key Points: 
  • BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer.
  • As part of a planned transition in connection with Mr. McLoughlin’s appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.
  • Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Lead, RSV at GSK.
  • “We are excited to welcome Sean to HilleVax’s executive team as we continue to progress NEST-IN1, our Phase 2b clinical trial of HIL-214 for the prevention of moderate-to-severe norovirus-related acute gastroenteritis,” said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax.

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

Retrieved on: 
Monday, January 8, 2024
IND, Sale, Research, Norovirus, Vaccine, Disease, Mortality, Virus-like particle, SHE, MD, Doctor of Philosophy, Investigational New Drug, VLP, Bioproduct, Safety, Pharmaceutical industry

HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.

Key Points: 
  • HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.
  • As part of the exclusive license agreement, Kangh will supply HIL-216 for use in HilleVax’s near-term clinical trials, including a Phase 1 trial that HilleVax expects to initiate in 2024.
  • “Our bivalent norovirus VLP vaccine candidate, HIL-214, remains the most advanced norovirus vaccine candidate in clinical development, and we are on-track to report topline safety and efficacy data in mid-2024 from our ongoing Phase 2b NEST-IN1 trial.
  • Kangh is also eligible to receive a single-digit tiered royalty on net sales outside of Greater China.

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Retrieved on: 
Thursday, December 21, 2023
Norovirus, Rotavirus, Mother, Pediatrics, Parent, SAN, Death, Vaxart, Pharmaceutical industry

There is no approved vaccine against norovirus, which sickens approximately 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work -- approximately 2.2 days on average -- to care for their children. The annual disease burden from norovirus is $10.6 billion in the U.S. alone.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.
  • “This is an important step forward as we drive toward a vaccine candidate that may make it possible for mothers to protect their children against this highly contagious – and potentially lethal -- virus.
  • We look forward to announcing topline data from this study by the end of 2024,” said Dr. James F. Cummings, Vaxart’s Chief Medical Officer.
  • Approximately 3 million sets of parents are forced by this virus to miss work -- approximately 2.2 days on average -- to care for their children.

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Viral, Protease, Research, Safety, Disease, MERS, Gastroenteritis, CFO, Influenza, COCP, Death, FDA, Vaccine, Merck, G&A, Pharmacokinetics, COVID-19, Therapy, CDC, RNA, R, SARS-CoV-2, Cocrystal, A, SARS, Enzyme, Pharmaceutical industry, Cryptocurrency, Medical device, Norovirus

Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.

Key Points: 
  • Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.
  • Research and development (R&D) expenses for the third quarter of 2023 were $4.2 million, compared with $3.9 million for the third quarter of 2022.
  • Cocrystal reported unrestricted cash as of September 30, 2023 of $29.7 million, compared with $37.1 million as of December 31, 2022.
  • The Company had working capital of $30.3 million and 10.2 million common shares outstanding as of September 30, 2023.

HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 9, 2023
VLP, Infant, Research, Vaccine, G&A, MD, Growth, Doctor of Philosophy, Norovirus, Pharmaceutical industry, Video game

Research and development expenses for the third quarter 2023 were $27.3 million, compared to $13.3 million for the third quarter 2022.

Key Points: 
  • Research and development expenses for the third quarter 2023 were $27.3 million, compared to $13.3 million for the third quarter 2022.
  • General and administrative expenses for the third quarter 2023 were $6.6 million, compared to $4.6 million for the third quarter 2022.
  • Other income for the third quarter 2023 was $2.1 million, compared to $1.1 million for the third quarter 2022.
  • Net loss for the third quarter 2023 was $31.8 million, compared to $16.8 million for the third quarter 2022.

EarthSafe Brings Hospital-Grade Hygiene to Homes with PurOne Everyday

Retrieved on: 
Tuesday, December 12, 2023
EPA, Logic, Safety, Tick, Tablet, Disinfectant, Fungus, Infection, Friends, COVID-19, Biofilm, Family, Hospital, Salmonella, Sports equipment, Environment, Dairy, Norovirus

BRAINTREE, Mass., Dec. 12, 2023 /PRNewswire/ -- When it comes to keeping spaces clean, there's a noticeable gap between the products used in hospitals and what's available at local stores. EarthSafe, the creators of the trusted EvaClean Infection Prevention Solution used in top hospitals, is changing the game by making its powerful bleach-free cleaner and disinfectant accessible to homes, businesses, and non-medical facilities.

Key Points: 
  • EarthSafe, developers of the EvaClean Infection Prevention Solution used in some of the nation's leading hospitals, creates PurOne Everyday Cleaner and Disinfectant to make healthcare-level hygiene attainable for everyone.
  • Steve Wilson, CEO of EarthSafe, shared his vision, stating, "PurOne Cleaner and Disinfectant, the core of the EvaClean Infection Prevention System, is now within reach for everyone.
  • With the introduction of PurOne Everyday, now anyone can elevate hygiene practices to better safeguard family, friends, customers, and staff from illnesses and infections."
  • PurOne Everyday ensures that everyone can benefit from using a safer, eco-friendly cleaning and disinfection solution.

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Research, Insurance, Vaxart, Three Months, Human, Congress, Conference, Bill, Bill & Melinda Gates Foundation, Ionel Floroiu, Mother, Vaccination, Disease, Clinical trial, COVID-19, Immunity, Webcast, Conference call, SAN, Vaccine, Pharmaceutical industry, Video game, Norovirus, Laninamivir

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2023.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the third quarter of 2023.
  • In October 2023, Vaxart senior management presented at the World Vaccine Congress Europe 2023 in Barcelona, Spain.
  • Vaxart reported a net loss of $17.4 million for the third quarter of 2023, compared to $29.3 million for the third quarter of 2022.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the third quarter of 2023 today, beginning at 4:30 p.m.

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Retrieved on: 
Thursday, November 2, 2023
Rotavirus, Death, Vaxart, Parent, Mother, Norovirus, SAN, Vaccine, Birth control

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.
  • “Initiating this study is an important step toward Vaxart’s goal of developing a vaccine that may reduce the significant global health threat norovirus poses to children under 5 years of age,” said Dr. James F. Cummings, Vaxart’s Chief Medical Officer.
  • “We believe an oral norovirus vaccine pill may make it possible for mothers to protect their infants against this highly contagious virus for which there currently is no approved vaccine.”
    Norovirus sickens approximately 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually.
  • This would translate into about 3 million sets of parents needing to take time from work (approximately 2.2 days on average) to care for their children.